Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Health
|
Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
|
Policies or Program
|
Health,
Industry
|
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
|
Policies or Program
|
Health
|
Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
|
Policies or Program
|
Health,
Industry
|
Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines
|
Regulation
|
Health,
Industry
|
Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
|
Regulation
|
Health,
Industry
|
Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.
|
Regulation
|
Health,
Industry
|
R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
|
Policies or Program,
Regulation
|
Health,
Industry
|
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
|
Policies or Program
|
Health,
Industry
|
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)
|
Policies or Program
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Date | DPOH, Position Title | Government Institution | Subject Matters |
---|---|---|
2024-09-26 |
|
Health, Industry |
2024-09-26 |
|
Health, Industry |
2024-09-24 |
|
Health, Industry |
2024-09-23 |
|
Health, Industry |
2024-09-23 |
|
Health, Industry |
2024-05-14 |
|
Health, Industry |
2024-05-14 |
|
Health, Industry |
2024-05-14 |
|
Health, Industry |
2024-05-13 |
|
Health, Industry |
2024-05-07 |
|
Health, Industry |
2024-05-07 |
|
Health, Industry |
2024-05-07 |
|
Health, Industry |
2024-02-29 |
|
Health, Industry, Research and Development |
2024-02-29 |
|
Health, Research and Development |
2024-02-29 |
|
Health, Industry, Science and Technology |
2023-12-07 |
|
Health, Industry, Science and Technology |
2023-11-08 |
|
Health, Industry, Science and Technology |
2023-11-07 |
|
Health, Science and Technology |
2023-11-06 |
|
Health |
2023-11-06 |
|
Health |
2023-11-06 |
|
Health, Industry |